Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations

Alexander Wong, Deborah Goldstein, Josep Mallolas, Edwin DeJesus, Margaret Johnson, Jean-Michel Molina, Anton Pozniak, Anthony Rodgers, Valerie Teal, Deborah Hepler, Sushma Kumar, Peter Sklar, George J Hanna, Carey Hwang, Cyrus Badshah, Hedy Teppler, Alexander Wong, Deborah Goldstein, Josep Mallolas, Edwin DeJesus, Margaret Johnson, Jean-Michel Molina, Anton Pozniak, Anthony Rodgers, Valerie Teal, Deborah Hepler, Sushma Kumar, Peter Sklar, George J Hanna, Carey Hwang, Cyrus Badshah, Hedy Teppler

Abstract

Supplemental Digital Content is Available in the Text.

Conflict of interest statement

The authors have no funding or conflicts of interest to disclose.

A.R., V.T., D.H., S.K., P.S., G.J.H., C.H., C.B., and H.T. are employees of Merck & Co., Inc., Kenilworth, NJ, and may own stock and/or hold stock options in the Company. J.-M.M. has received honoraria from Gilead Sciences, Inc, Foster City, CA, and Merck, Sharp, & Dohme Corp, a subsidiary of Merck & Co., Inc., Kenilworth, NJ for participating in advisory boards and has received a research grant from Gilead Sciences Inc. The remaining authors have no conflicts of interest to disclose.

References

    1. Buchacz K, Young B, Palella FJ, Jr, et al. Trends in use of genotypic resistance testing and frequency of major drug resistance among antiretroviral-naive persons in the HIV Outpatient Study, 1999–2011. J Antimicrob Chemother. 2015;70:2337–2346.
    1. Gupta RK, Gregson J, Parkin N, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis. 2018;18:346–355.
    1. Frentz D, Van de Vijver DA, Abecasis AB, et al. Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. BMC Infect Dis. 2014;14:407.
    1. Zazzi M, Hu H, Prosperi M. The global burden of HIV-1 drug resistance in the past 20 years. PeerJ. 2018;6:e4848.
    1. British HIV Association. BHIVA Guidelines for the Treatment of HIV-1-Positive Adults With Antiretroviral Therapy 2015 (2016 Interim Update) Available at: . Accessed October 29, 2018.
    1. Department of Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV; 2018. Available at: . Accessed October 29, 2018.
    1. Anderson MS, Gilmartin J, Cilissen C, et al. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. Antivir Ther (Lond). 2015;20:397–405.
    1. Colombier MA, Molina JM. Doravirine: a review. Curr Opin HIV AIDS. 2018;13:308–314.
    1. Feng M, Sachs NA, Xu M, et al. Doravirine suppresses common nonnucleoside reverse transcriptase inhibitor-associated mutants at clinically relevant concentrations. Antimicrob Agents Chemother. 2016;60:2241–2247.
    1. Feng M, Wang D, Grobler JA, et al. In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways. Antimicrob Agents Chemother. 2015;59:590–598.
    1. Smith SJ, Pauly GT, Akram A, et al. Rilpivirine and doravirine have complementary efficacies against NNRTI-resistant HIV-1 mutants. J Acquir Immune Defic Syndr. 2016;72:485–491.
    1. U.S. Department of Health and Human Services, National Institutes of Health. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.0. [November 2014]. Available at: . Accessed October 29, 2018.
    1. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of binomial. Biometrika. 1934;26:404–413.
    1. Johnson M, Kumar P, Molina JM, et al. Switching to Doravirine/Lamivudine/Tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT trial. J Acquir Immune Defic Syndr 2019;81:463–472.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere